Recommandations françaises de prise en charge des tumeurs d’Ewing métastatiques extra-pulmonaires (GroupOs)
Bulletin du Cancer · 2025
DOI: 10.1016/j.bulcan.2024.01.014 ↗Kurz gefasst
Leitlinie in der Zeitschrift Bulletin du Cancer, 2025. Verfasst von Sarah Winter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre intégré de soins et de recherche en oncologie de l'enfant, adolescent et jeune adulte (SIREDO), Institut Curie, Paris, France. Electronic addr…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Sarcoma, Ewing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination. Main recommendations include induction chemotherapy with nine cycles of vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide. In case of insufficient response, other chemotherapy combination or inclusion in a clinical trial should be considered. Induction chemotherapy should be followed by local treatment, consisting of surgery and/or radiotherapy. Optimal local treatment is a milestone in the management of patients with Ewing sarcoma and should be discussed with experts and surgeons/radiotherapists working in the sarcoma network. High-dose chemotherapy (HDC) containing busulfan and melphalan followed by autologous stem-cell transplantation is still unclear, with contradictory results. HDC will then be discussed in national tumor board and administered to patients when compatible with local treatment. Given the high relapse rate observed among these metastatic patients, maintenance chemotherapy (so called metronomic regimen) will then be given for two years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre intégré de soins et de recherche en oncologie de l'enfant, adolescent et jeune adulte (SIREDO), Institut Curie, Paris, France. Electronic address: sarah.winter@curie.fr.
- Oncologie médicale, IUCT Oncopole, Toulouse, France.
- Radiothérapie, IUCT Oncopole, Toulouse, France.
- Radiothérapie, Institut Curie, Paris, France.
- Oncologie pédiatrique et adolescents, Institut Gustave-Roussy, Paris, France.
- Centre intégré de soins et de recherche en oncologie de l'enfant, adolescent et jeune adulte (SIREDO), Institut Curie, Paris, France.
Zitieren
APA
Winter, S., Valentin, T., Ducassou, A., Helfre, S., Berlanga, P., Lemelle, L., Marie-Cardine, A., Rouquette, P. B., & Laurence, V. (2025). Recommandations françaises de prise en charge des tumeurs d’Ewing métastatiques extra-pulmonaires (GroupOs). Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2024.01.014
Vancouver
Winter S, Valentin T, Ducassou A, Helfre S, Berlanga P, Lemelle L, et al. Recommandations françaises de prise en charge des tumeurs d’Ewing métastatiques extra-pulmonaires (GroupOs). Bulletin du Cancer. 2025. doi:10.1016/j.bulcan.2024.01.014
BibTeX
@article{Winter2025,
author = {Winter, Sarah and Valentin, Thibaud and Ducassou, Anne and Helfre, Sylvie and Berlanga, Pablo and Lemelle, Lauriane and Marie-Cardine, Aude and Rouquette, Pascaline Boudou and Laurence, Valérie},
title = {Recommandations françaises de prise en charge des tumeurs d’Ewing métastatiques extra-pulmonaires (GroupOs)},
journal = {Bulletin du Cancer},
year = {2025},
doi = {10.1016/j.bulcan.2024.01.014}
}
EUVIMED